nodes	percent_of_prediction	percent_of_DWPC	metapath
Nabilone—Mood swings—Sorafenib—thyroid cancer	0.00822	0.00881	CcSEcCtD
Nabilone—Muscle relaxant therapy—Doxorubicin—thyroid cancer	0.00822	0.0088	CcSEcCtD
Nabilone—Arrhythmia—Vandetanib—thyroid cancer	0.00795	0.00852	CcSEcCtD
Nabilone—Body temperature decreased—Epirubicin—thyroid cancer	0.00788	0.00844	CcSEcCtD
Nabilone—Hypothermia—Epirubicin—thyroid cancer	0.00788	0.00844	CcSEcCtD
Nabilone—Hypotonia—Doxorubicin—thyroid cancer	0.00778	0.00833	CcSEcCtD
Nabilone—Gastritis—Sorafenib—thyroid cancer	0.00768	0.00823	CcSEcCtD
Nabilone—Vision blurred—Vandetanib—thyroid cancer	0.0073	0.00782	CcSEcCtD
Nabilone—Body temperature decreased—Doxorubicin—thyroid cancer	0.00729	0.00781	CcSEcCtD
Nabilone—Hypothermia—Doxorubicin—thyroid cancer	0.00729	0.00781	CcSEcCtD
Nabilone—Tremor—Vandetanib—thyroid cancer	0.00726	0.00777	CcSEcCtD
Nabilone—Loss of consciousness—Vandetanib—thyroid cancer	0.00681	0.00729	CcSEcCtD
Nabilone—Cough—Vandetanib—thyroid cancer	0.00676	0.00724	CcSEcCtD
Nabilone—Convulsion—Vandetanib—thyroid cancer	0.00671	0.00719	CcSEcCtD
Nabilone—Hypertension—Vandetanib—thyroid cancer	0.00669	0.00716	CcSEcCtD
Nabilone—Arthralgia—Vandetanib—thyroid cancer	0.0066	0.00706	CcSEcCtD
Nabilone—Chest pain—Vandetanib—thyroid cancer	0.0066	0.00706	CcSEcCtD
Nabilone—Anxiety—Vandetanib—thyroid cancer	0.00657	0.00704	CcSEcCtD
Nabilone—Stomatitis—Sorafenib—thyroid cancer	0.00652	0.00698	CcSEcCtD
Nabilone—Dry mouth—Vandetanib—thyroid cancer	0.00645	0.00691	CcSEcCtD
Nabilone—Epistaxis—Sorafenib—thyroid cancer	0.00631	0.00676	CcSEcCtD
Nabilone—Infection—Vandetanib—thyroid cancer	0.00628	0.00673	CcSEcCtD
Nabilone—Scotoma—Epirubicin—thyroid cancer	0.00582	0.00623	CcSEcCtD
Nabilone—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00576	0.00617	CcSEcCtD
Nabilone—Amblyopia—Epirubicin—thyroid cancer	0.00572	0.00613	CcSEcCtD
Nabilone—Insomnia—Vandetanib—thyroid cancer	0.00572	0.00613	CcSEcCtD
Nabilone—Paraesthesia—Vandetanib—thyroid cancer	0.00568	0.00608	CcSEcCtD
Nabilone—Dyspnoea—Vandetanib—thyroid cancer	0.00564	0.00604	CcSEcCtD
Nabilone—Tinnitus—Sorafenib—thyroid cancer	0.0056	0.006	CcSEcCtD
Nabilone—Flushing—Sorafenib—thyroid cancer	0.00557	0.00597	CcSEcCtD
Nabilone—Dyspepsia—Vandetanib—thyroid cancer	0.00557	0.00596	CcSEcCtD
Nabilone—Decreased appetite—Vandetanib—thyroid cancer	0.0055	0.00589	CcSEcCtD
Nabilone—Fatigue—Vandetanib—thyroid cancer	0.00545	0.00584	CcSEcCtD
Nabilone—Constipation—Vandetanib—thyroid cancer	0.00541	0.00579	CcSEcCtD
Nabilone—Pain—Vandetanib—thyroid cancer	0.00541	0.00579	CcSEcCtD
Nabilone—Scotoma—Doxorubicin—thyroid cancer	0.00538	0.00577	CcSEcCtD
Nabilone—Arrhythmia—Sorafenib—thyroid cancer	0.00536	0.00574	CcSEcCtD
Nabilone—Amblyopia—Doxorubicin—thyroid cancer	0.0053	0.00567	CcSEcCtD
Nabilone—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00517	0.00554	CcSEcCtD
Nabilone—Abdominal pain—Vandetanib—thyroid cancer	0.005	0.00535	CcSEcCtD
Nabilone—Body temperature increased—Vandetanib—thyroid cancer	0.005	0.00535	CcSEcCtD
Nabilone—Anaemia—Sorafenib—thyroid cancer	0.00483	0.00517	CcSEcCtD
Nabilone—Thinking abnormal—Epirubicin—thyroid cancer	0.00483	0.00517	CcSEcCtD
Nabilone—Syncope—Sorafenib—thyroid cancer	0.00469	0.00502	CcSEcCtD
Nabilone—Leukopenia—Sorafenib—thyroid cancer	0.00468	0.00501	CcSEcCtD
Nabilone—Loss of consciousness—Sorafenib—thyroid cancer	0.00459	0.00492	CcSEcCtD
Nabilone—Cough—Sorafenib—thyroid cancer	0.00456	0.00488	CcSEcCtD
Nabilone—Asthenia—Vandetanib—thyroid cancer	0.00454	0.00486	CcSEcCtD
Nabilone—Hypertension—Sorafenib—thyroid cancer	0.00451	0.00483	CcSEcCtD
Nabilone—Coordination abnormal—Epirubicin—thyroid cancer	0.0045	0.00482	CcSEcCtD
Nabilone—Pruritus—Vandetanib—thyroid cancer	0.00447	0.00479	CcSEcCtD
Nabilone—Neck pain—Epirubicin—thyroid cancer	0.00447	0.00479	CcSEcCtD
Nabilone—Thinking abnormal—Doxorubicin—thyroid cancer	0.00447	0.00478	CcSEcCtD
Nabilone—Myalgia—Sorafenib—thyroid cancer	0.00445	0.00477	CcSEcCtD
Nabilone—Arthralgia—Sorafenib—thyroid cancer	0.00445	0.00477	CcSEcCtD
Nabilone—Abnormal dreams—Epirubicin—thyroid cancer	0.00437	0.00468	CcSEcCtD
Nabilone—Dry mouth—Sorafenib—thyroid cancer	0.00435	0.00466	CcSEcCtD
Nabilone—Diarrhoea—Vandetanib—thyroid cancer	0.00433	0.00463	CcSEcCtD
Nabilone—Infection—Sorafenib—thyroid cancer	0.00424	0.00454	CcSEcCtD
Nabilone—Shock—Sorafenib—thyroid cancer	0.0042	0.00449	CcSEcCtD
Nabilone—Dizziness—Vandetanib—thyroid cancer	0.00418	0.00448	CcSEcCtD
Nabilone—Coordination abnormal—Doxorubicin—thyroid cancer	0.00416	0.00446	CcSEcCtD
Nabilone—Neck pain—Doxorubicin—thyroid cancer	0.00414	0.00443	CcSEcCtD
Nabilone—Dry eye—Epirubicin—thyroid cancer	0.00408	0.00437	CcSEcCtD
Nabilone—Anorexia—Sorafenib—thyroid cancer	0.00407	0.00435	CcSEcCtD
Nabilone—Abnormal dreams—Doxorubicin—thyroid cancer	0.00404	0.00433	CcSEcCtD
Nabilone—Coma—Epirubicin—thyroid cancer	0.00404	0.00432	CcSEcCtD
Nabilone—Vomiting—Vandetanib—thyroid cancer	0.00402	0.00431	CcSEcCtD
Nabilone—Rash—Vandetanib—thyroid cancer	0.00399	0.00427	CcSEcCtD
Nabilone—Dermatitis—Vandetanib—thyroid cancer	0.00398	0.00427	CcSEcCtD
Nabilone—Headache—Vandetanib—thyroid cancer	0.00396	0.00424	CcSEcCtD
Nabilone—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00389	0.00416	CcSEcCtD
Nabilone—Mental disability—Epirubicin—thyroid cancer	0.00384	0.00411	CcSEcCtD
Nabilone—CNR2—GPCR ligand binding—CALCB—thyroid cancer	0.00383	0.0579	CbGpPWpGaD
Nabilone—Dyspnoea—Sorafenib—thyroid cancer	0.0038	0.00407	CcSEcCtD
Nabilone—Dry eye—Doxorubicin—thyroid cancer	0.00378	0.00404	CcSEcCtD
Nabilone—Nausea—Vandetanib—thyroid cancer	0.00376	0.00402	CcSEcCtD
Nabilone—Dyspepsia—Sorafenib—thyroid cancer	0.00376	0.00402	CcSEcCtD
Nabilone—Coma—Doxorubicin—thyroid cancer	0.00374	0.004	CcSEcCtD
Nabilone—Decreased appetite—Sorafenib—thyroid cancer	0.00371	0.00397	CcSEcCtD
Nabilone—Fatigue—Sorafenib—thyroid cancer	0.00368	0.00394	CcSEcCtD
Nabilone—Photosensitivity—Epirubicin—thyroid cancer	0.00365	0.00391	CcSEcCtD
Nabilone—Constipation—Sorafenib—thyroid cancer	0.00365	0.00391	CcSEcCtD
Nabilone—Pain—Sorafenib—thyroid cancer	0.00365	0.00391	CcSEcCtD
Nabilone—Mental disability—Doxorubicin—thyroid cancer	0.00355	0.0038	CcSEcCtD
Nabilone—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00349	0.00374	CcSEcCtD
Nabilone—Hot flush—Epirubicin—thyroid cancer	0.00343	0.00367	CcSEcCtD
Nabilone—Increased appetite—Epirubicin—thyroid cancer	0.00341	0.00366	CcSEcCtD
Nabilone—Menopausal symptoms—Epirubicin—thyroid cancer	0.0034	0.00364	CcSEcCtD
Nabilone—Photosensitivity—Doxorubicin—thyroid cancer	0.00338	0.00362	CcSEcCtD
Nabilone—Body temperature increased—Sorafenib—thyroid cancer	0.00337	0.00361	CcSEcCtD
Nabilone—Abdominal pain—Sorafenib—thyroid cancer	0.00337	0.00361	CcSEcCtD
Nabilone—Cerebrovascular accident—Epirubicin—thyroid cancer	0.00327	0.00351	CcSEcCtD
Nabilone—Hot flush—Doxorubicin—thyroid cancer	0.00317	0.0034	CcSEcCtD
Nabilone—Increased appetite—Doxorubicin—thyroid cancer	0.00316	0.00338	CcSEcCtD
Nabilone—Affect lability—Epirubicin—thyroid cancer	0.00316	0.00338	CcSEcCtD
Nabilone—Menopausal symptoms—Doxorubicin—thyroid cancer	0.00315	0.00337	CcSEcCtD
Nabilone—Hypersensitivity—Sorafenib—thyroid cancer	0.00314	0.00337	CcSEcCtD
Nabilone—Face oedema—Epirubicin—thyroid cancer	0.0031	0.00332	CcSEcCtD
Nabilone—Asthenia—Sorafenib—thyroid cancer	0.00306	0.00328	CcSEcCtD
Nabilone—Mood swings—Epirubicin—thyroid cancer	0.00304	0.00325	CcSEcCtD
Nabilone—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.00303	0.00324	CcSEcCtD
Nabilone—Pruritus—Sorafenib—thyroid cancer	0.00302	0.00323	CcSEcCtD
Nabilone—Ataxia—Epirubicin—thyroid cancer	0.00302	0.00323	CcSEcCtD
Nabilone—CNR1—GPCR ligand binding—CALCB—thyroid cancer	0.00301	0.0455	CbGpPWpGaD
Nabilone—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00293	0.00314	CcSEcCtD
Nabilone—Affect lability—Doxorubicin—thyroid cancer	0.00292	0.00313	CcSEcCtD
Nabilone—Diarrhoea—Sorafenib—thyroid cancer	0.00292	0.00313	CcSEcCtD
Nabilone—Face oedema—Doxorubicin—thyroid cancer	0.00287	0.00307	CcSEcCtD
Nabilone—Gastritis—Epirubicin—thyroid cancer	0.00284	0.00304	CcSEcCtD
Nabilone—Dizziness—Sorafenib—thyroid cancer	0.00282	0.00302	CcSEcCtD
Nabilone—Mood swings—Doxorubicin—thyroid cancer	0.00281	0.00301	CcSEcCtD
Nabilone—Ataxia—Doxorubicin—thyroid cancer	0.00279	0.00299	CcSEcCtD
Nabilone—Vomiting—Sorafenib—thyroid cancer	0.00271	0.0029	CcSEcCtD
Nabilone—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.00271	0.0029	CcSEcCtD
Nabilone—Rash—Sorafenib—thyroid cancer	0.00269	0.00288	CcSEcCtD
Nabilone—Dermatitis—Sorafenib—thyroid cancer	0.00269	0.00288	CcSEcCtD
Nabilone—Headache—Sorafenib—thyroid cancer	0.00267	0.00286	CcSEcCtD
Nabilone—Gastritis—Doxorubicin—thyroid cancer	0.00263	0.00281	CcSEcCtD
Nabilone—Pollakiuria—Epirubicin—thyroid cancer	0.00256	0.00274	CcSEcCtD
Nabilone—Nausea—Sorafenib—thyroid cancer	0.00253	0.00271	CcSEcCtD
Nabilone—Photosensitivity reaction—Epirubicin—thyroid cancer	0.00253	0.00271	CcSEcCtD
Nabilone—Drowsiness—Epirubicin—thyroid cancer	0.00247	0.00265	CcSEcCtD
Nabilone—Stomatitis—Epirubicin—thyroid cancer	0.00241	0.00258	CcSEcCtD
Nabilone—Pollakiuria—Doxorubicin—thyroid cancer	0.00237	0.00254	CcSEcCtD
Nabilone—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00234	0.00251	CcSEcCtD
Nabilone—Epistaxis—Epirubicin—thyroid cancer	0.00233	0.0025	CcSEcCtD
Nabilone—CNR2—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00233	0.0352	CbGpPWpGaD
Nabilone—Drowsiness—Doxorubicin—thyroid cancer	0.00229	0.00245	CcSEcCtD
Nabilone—CNR2—G alpha (i) signalling events—SST—thyroid cancer	0.00228	0.0345	CbGpPWpGaD
Nabilone—Stomatitis—Doxorubicin—thyroid cancer	0.00223	0.00239	CcSEcCtD
Nabilone—Hypoaesthesia—Epirubicin—thyroid cancer	0.00221	0.00236	CcSEcCtD
Nabilone—Pharyngitis—Epirubicin—thyroid cancer	0.0022	0.00236	CcSEcCtD
Nabilone—CNR2—GPCR downstream signaling—CALCB—thyroid cancer	0.00217	0.0327	CbGpPWpGaD
Nabilone—Epistaxis—Doxorubicin—thyroid cancer	0.00216	0.00231	CcSEcCtD
Nabilone—Visual impairment—Epirubicin—thyroid cancer	0.00214	0.00229	CcSEcCtD
Nabilone—Eye disorder—Epirubicin—thyroid cancer	0.00207	0.00222	CcSEcCtD
Nabilone—Tinnitus—Epirubicin—thyroid cancer	0.00207	0.00222	CcSEcCtD
Nabilone—Flushing—Epirubicin—thyroid cancer	0.00206	0.00221	CcSEcCtD
Nabilone—Hypoaesthesia—Doxorubicin—thyroid cancer	0.00204	0.00219	CcSEcCtD
Nabilone—Pharyngitis—Doxorubicin—thyroid cancer	0.00204	0.00218	CcSEcCtD
Nabilone—Chills—Epirubicin—thyroid cancer	0.00199	0.00213	CcSEcCtD
Nabilone—Arrhythmia—Epirubicin—thyroid cancer	0.00198	0.00212	CcSEcCtD
Nabilone—Visual impairment—Doxorubicin—thyroid cancer	0.00198	0.00212	CcSEcCtD
Nabilone—CNR2—Signaling by GPCR—CALCB—thyroid cancer	0.00197	0.0297	CbGpPWpGaD
Nabilone—Eye disorder—Doxorubicin—thyroid cancer	0.00192	0.00205	CcSEcCtD
Nabilone—Tinnitus—Doxorubicin—thyroid cancer	0.00191	0.00205	CcSEcCtD
Nabilone—Flushing—Doxorubicin—thyroid cancer	0.00191	0.00204	CcSEcCtD
Nabilone—Tension—Epirubicin—thyroid cancer	0.0019	0.00203	CcSEcCtD
Nabilone—Nervousness—Epirubicin—thyroid cancer	0.00188	0.00201	CcSEcCtD
Nabilone—Back pain—Epirubicin—thyroid cancer	0.00187	0.002	CcSEcCtD
Nabilone—Chills—Doxorubicin—thyroid cancer	0.00184	0.00197	CcSEcCtD
Nabilone—Arrhythmia—Doxorubicin—thyroid cancer	0.00183	0.00196	CcSEcCtD
Nabilone—CNR1—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00183	0.0276	CbGpPWpGaD
Nabilone—Vision blurred—Epirubicin—thyroid cancer	0.00182	0.00195	CcSEcCtD
Nabilone—CNR2—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00181	0.0274	CbGpPWpGaD
Nabilone—Ill-defined disorder—Epirubicin—thyroid cancer	0.00179	0.00192	CcSEcCtD
Nabilone—CNR1—G alpha (i) signalling events—SST—thyroid cancer	0.00179	0.027	CbGpPWpGaD
Nabilone—Anaemia—Epirubicin—thyroid cancer	0.00179	0.00191	CcSEcCtD
Nabilone—Agitation—Epirubicin—thyroid cancer	0.00178	0.0019	CcSEcCtD
Nabilone—CNR2—GPCR ligand binding—TSHR—thyroid cancer	0.00177	0.0268	CbGpPWpGaD
Nabilone—Tension—Doxorubicin—thyroid cancer	0.00175	0.00188	CcSEcCtD
Nabilone—Malaise—Epirubicin—thyroid cancer	0.00174	0.00187	CcSEcCtD
Nabilone—Nervousness—Doxorubicin—thyroid cancer	0.00174	0.00186	CcSEcCtD
Nabilone—Vertigo—Epirubicin—thyroid cancer	0.00174	0.00186	CcSEcCtD
Nabilone—Syncope—Epirubicin—thyroid cancer	0.00173	0.00186	CcSEcCtD
Nabilone—Leukopenia—Epirubicin—thyroid cancer	0.00173	0.00185	CcSEcCtD
Nabilone—Back pain—Doxorubicin—thyroid cancer	0.00173	0.00185	CcSEcCtD
Nabilone—Palpitations—Epirubicin—thyroid cancer	0.00171	0.00183	CcSEcCtD
Nabilone—CNR1—GPCR downstream signaling—CALCB—thyroid cancer	0.0017	0.0257	CbGpPWpGaD
Nabilone—Loss of consciousness—Epirubicin—thyroid cancer	0.0017	0.00182	CcSEcCtD
Nabilone—Cough—Epirubicin—thyroid cancer	0.00169	0.00181	CcSEcCtD
Nabilone—Vision blurred—Doxorubicin—thyroid cancer	0.00168	0.0018	CcSEcCtD
Nabilone—Convulsion—Epirubicin—thyroid cancer	0.00167	0.00179	CcSEcCtD
Nabilone—Hypertension—Epirubicin—thyroid cancer	0.00167	0.00179	CcSEcCtD
Nabilone—Ill-defined disorder—Doxorubicin—thyroid cancer	0.00166	0.00178	CcSEcCtD
Nabilone—Anaemia—Doxorubicin—thyroid cancer	0.00165	0.00177	CcSEcCtD
Nabilone—Arthralgia—Epirubicin—thyroid cancer	0.00164	0.00176	CcSEcCtD
Nabilone—Myalgia—Epirubicin—thyroid cancer	0.00164	0.00176	CcSEcCtD
Nabilone—Chest pain—Epirubicin—thyroid cancer	0.00164	0.00176	CcSEcCtD
Nabilone—Agitation—Doxorubicin—thyroid cancer	0.00164	0.00176	CcSEcCtD
Nabilone—Anxiety—Epirubicin—thyroid cancer	0.00164	0.00176	CcSEcCtD
Nabilone—Discomfort—Epirubicin—thyroid cancer	0.00163	0.00174	CcSEcCtD
Nabilone—Malaise—Doxorubicin—thyroid cancer	0.00161	0.00173	CcSEcCtD
Nabilone—Dry mouth—Epirubicin—thyroid cancer	0.00161	0.00172	CcSEcCtD
Nabilone—Vertigo—Doxorubicin—thyroid cancer	0.00161	0.00172	CcSEcCtD
Nabilone—Syncope—Doxorubicin—thyroid cancer	0.0016	0.00172	CcSEcCtD
Nabilone—Leukopenia—Doxorubicin—thyroid cancer	0.0016	0.00171	CcSEcCtD
Nabilone—Confusional state—Epirubicin—thyroid cancer	0.00159	0.0017	CcSEcCtD
Nabilone—Palpitations—Doxorubicin—thyroid cancer	0.00158	0.00169	CcSEcCtD
Nabilone—Loss of consciousness—Doxorubicin—thyroid cancer	0.00157	0.00168	CcSEcCtD
Nabilone—Infection—Epirubicin—thyroid cancer	0.00157	0.00168	CcSEcCtD
Nabilone—Cough—Doxorubicin—thyroid cancer	0.00156	0.00167	CcSEcCtD
Nabilone—Shock—Epirubicin—thyroid cancer	0.00155	0.00166	CcSEcCtD
Nabilone—Convulsion—Doxorubicin—thyroid cancer	0.00155	0.00166	CcSEcCtD
Nabilone—Hypertension—Doxorubicin—thyroid cancer	0.00154	0.00165	CcSEcCtD
Nabilone—CNR1—Signaling by GPCR—CALCB—thyroid cancer	0.00154	0.0233	CbGpPWpGaD
Nabilone—Tachycardia—Epirubicin—thyroid cancer	0.00154	0.00165	CcSEcCtD
Nabilone—Hyperhidrosis—Epirubicin—thyroid cancer	0.00152	0.00163	CcSEcCtD
Nabilone—Chest pain—Doxorubicin—thyroid cancer	0.00152	0.00163	CcSEcCtD
Nabilone—Arthralgia—Doxorubicin—thyroid cancer	0.00152	0.00163	CcSEcCtD
Nabilone—Myalgia—Doxorubicin—thyroid cancer	0.00152	0.00163	CcSEcCtD
Nabilone—Anxiety—Doxorubicin—thyroid cancer	0.00152	0.00162	CcSEcCtD
Nabilone—CNR2—GPCR ligand binding—PTCH1—thyroid cancer	0.00151	0.0228	CbGpPWpGaD
Nabilone—Discomfort—Doxorubicin—thyroid cancer	0.0015	0.00161	CcSEcCtD
Nabilone—Anorexia—Epirubicin—thyroid cancer	0.0015	0.00161	CcSEcCtD
Nabilone—Dry mouth—Doxorubicin—thyroid cancer	0.00149	0.00159	CcSEcCtD
Nabilone—Hypotension—Epirubicin—thyroid cancer	0.00147	0.00158	CcSEcCtD
Nabilone—Confusional state—Doxorubicin—thyroid cancer	0.00147	0.00158	CcSEcCtD
Nabilone—Infection—Doxorubicin—thyroid cancer	0.00145	0.00155	CcSEcCtD
Nabilone—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00144	0.00154	CcSEcCtD
Nabilone—Shock—Doxorubicin—thyroid cancer	0.00144	0.00154	CcSEcCtD
Nabilone—Insomnia—Epirubicin—thyroid cancer	0.00143	0.00153	CcSEcCtD
Nabilone—Tachycardia—Doxorubicin—thyroid cancer	0.00142	0.00152	CcSEcCtD
Nabilone—CNR1—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00142	0.0215	CbGpPWpGaD
Nabilone—Paraesthesia—Epirubicin—thyroid cancer	0.00142	0.00152	CcSEcCtD
Nabilone—Hyperhidrosis—Doxorubicin—thyroid cancer	0.00141	0.00151	CcSEcCtD
Nabilone—Dyspnoea—Epirubicin—thyroid cancer	0.00141	0.00151	CcSEcCtD
Nabilone—Somnolence—Epirubicin—thyroid cancer	0.0014	0.0015	CcSEcCtD
Nabilone—CNR1—GPCR ligand binding—TSHR—thyroid cancer	0.00139	0.021	CbGpPWpGaD
Nabilone—Anorexia—Doxorubicin—thyroid cancer	0.00139	0.00149	CcSEcCtD
Nabilone—Dyspepsia—Epirubicin—thyroid cancer	0.00139	0.00149	CcSEcCtD
Nabilone—CNR2—GPCR ligand binding—SST—thyroid cancer	0.00138	0.0209	CbGpPWpGaD
Nabilone—Decreased appetite—Epirubicin—thyroid cancer	0.00137	0.00147	CcSEcCtD
Nabilone—Hypotension—Doxorubicin—thyroid cancer	0.00136	0.00146	CcSEcCtD
Nabilone—Fatigue—Epirubicin—thyroid cancer	0.00136	0.00146	CcSEcCtD
Nabilone—Constipation—Epirubicin—thyroid cancer	0.00135	0.00144	CcSEcCtD
Nabilone—Pain—Epirubicin—thyroid cancer	0.00135	0.00144	CcSEcCtD
Nabilone—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00133	0.00142	CcSEcCtD
Nabilone—CNR2—GPCR ligand binding—CALCA—thyroid cancer	0.00133	0.0201	CbGpPWpGaD
Nabilone—Insomnia—Doxorubicin—thyroid cancer	0.00132	0.00141	CcSEcCtD
Nabilone—Paraesthesia—Doxorubicin—thyroid cancer	0.00131	0.0014	CcSEcCtD
Nabilone—Dyspnoea—Doxorubicin—thyroid cancer	0.0013	0.00139	CcSEcCtD
Nabilone—Feeling abnormal—Epirubicin—thyroid cancer	0.0013	0.00139	CcSEcCtD
Nabilone—Somnolence—Doxorubicin—thyroid cancer	0.0013	0.00139	CcSEcCtD
Nabilone—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00129	0.00138	CcSEcCtD
Nabilone—Dyspepsia—Doxorubicin—thyroid cancer	0.00128	0.00138	CcSEcCtD
Nabilone—Decreased appetite—Doxorubicin—thyroid cancer	0.00127	0.00136	CcSEcCtD
Nabilone—Fatigue—Doxorubicin—thyroid cancer	0.00126	0.00135	CcSEcCtD
Nabilone—Pain—Doxorubicin—thyroid cancer	0.00125	0.00134	CcSEcCtD
Nabilone—Constipation—Doxorubicin—thyroid cancer	0.00125	0.00134	CcSEcCtD
Nabilone—Abdominal pain—Epirubicin—thyroid cancer	0.00125	0.00133	CcSEcCtD
Nabilone—Body temperature increased—Epirubicin—thyroid cancer	0.00125	0.00133	CcSEcCtD
Nabilone—Feeling abnormal—Doxorubicin—thyroid cancer	0.0012	0.00129	CcSEcCtD
Nabilone—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00119	0.00128	CcSEcCtD
Nabilone—CNR1—GPCR ligand binding—PTCH1—thyroid cancer	0.00118	0.0179	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—CALCB—thyroid cancer	0.00116	0.0176	CbGpPWpGaD
Nabilone—Hypersensitivity—Epirubicin—thyroid cancer	0.00116	0.00124	CcSEcCtD
Nabilone—Body temperature increased—Doxorubicin—thyroid cancer	0.00115	0.00123	CcSEcCtD
Nabilone—Abdominal pain—Doxorubicin—thyroid cancer	0.00115	0.00123	CcSEcCtD
Nabilone—Asthenia—Epirubicin—thyroid cancer	0.00113	0.00121	CcSEcCtD
Nabilone—Pruritus—Epirubicin—thyroid cancer	0.00112	0.00119	CcSEcCtD
Nabilone—CNR2—Signaling Pathways—TRIM33—thyroid cancer	0.0011	0.0167	CbGpPWpGaD
Nabilone—CNR1—GPCR ligand binding—SST—thyroid cancer	0.00108	0.0164	CbGpPWpGaD
Nabilone—Diarrhoea—Epirubicin—thyroid cancer	0.00108	0.00116	CcSEcCtD
Nabilone—Hypersensitivity—Doxorubicin—thyroid cancer	0.00107	0.00115	CcSEcCtD
Nabilone—Asthenia—Doxorubicin—thyroid cancer	0.00105	0.00112	CcSEcCtD
Nabilone—Dizziness—Epirubicin—thyroid cancer	0.00104	0.00112	CcSEcCtD
Nabilone—CNR1—GPCR ligand binding—CALCA—thyroid cancer	0.00104	0.0158	CbGpPWpGaD
Nabilone—Pruritus—Doxorubicin—thyroid cancer	0.00103	0.00111	CcSEcCtD
Nabilone—CNR2—GPCR downstream signaling—TSHR—thyroid cancer	0.001	0.0152	CbGpPWpGaD
Nabilone—Vomiting—Epirubicin—thyroid cancer	0.001	0.00107	CcSEcCtD
Nabilone—Diarrhoea—Doxorubicin—thyroid cancer	0.000998	0.00107	CcSEcCtD
Nabilone—Rash—Epirubicin—thyroid cancer	0.000994	0.00106	CcSEcCtD
Nabilone—Dermatitis—Epirubicin—thyroid cancer	0.000993	0.00106	CcSEcCtD
Nabilone—Headache—Epirubicin—thyroid cancer	0.000988	0.00106	CcSEcCtD
Nabilone—Dizziness—Doxorubicin—thyroid cancer	0.000965	0.00103	CcSEcCtD
Nabilone—Nausea—Epirubicin—thyroid cancer	0.000937	0.001	CcSEcCtD
Nabilone—Vomiting—Doxorubicin—thyroid cancer	0.000928	0.000993	CcSEcCtD
Nabilone—Rash—Doxorubicin—thyroid cancer	0.00092	0.000985	CcSEcCtD
Nabilone—Dermatitis—Doxorubicin—thyroid cancer	0.000919	0.000984	CcSEcCtD
Nabilone—Headache—Doxorubicin—thyroid cancer	0.000914	0.000979	CcSEcCtD
Nabilone—CNR1—Signaling Pathways—CALCB—thyroid cancer	0.000912	0.0138	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—TSHR—thyroid cancer	0.00091	0.0138	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000896	0.0135	CbGpPWpGaD
Nabilone—Nausea—Doxorubicin—thyroid cancer	0.000867	0.000928	CcSEcCtD
Nabilone—CNR1—Signaling Pathways—TRIM33—thyroid cancer	0.000864	0.0131	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—TSHR—thyroid cancer	0.000787	0.0119	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—SST—thyroid cancer	0.00078	0.0118	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—PTCH1—thyroid cancer	0.000774	0.0117	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—CALCA—thyroid cancer	0.000751	0.0113	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—TCF7L1—thyroid cancer	0.000735	0.0111	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—TSHR—thyroid cancer	0.000714	0.0108	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—SST—thyroid cancer	0.000708	0.0107	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000703	0.0106	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—CALCA—thyroid cancer	0.000682	0.0103	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—CDK1—thyroid cancer	0.000617	0.00933	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—SST—thyroid cancer	0.000612	0.00925	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—PTCH1—thyroid cancer	0.000607	0.00918	CbGpPWpGaD
Nabilone—CNR1—BDNF signaling pathway—HRAS—thyroid cancer	0.000605	0.00915	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—CALCA—thyroid cancer	0.000589	0.0089	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—TCF7L1—thyroid cancer	0.000577	0.00872	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—SST—thyroid cancer	0.000556	0.0084	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—TSHR—thyroid cancer	0.000538	0.00813	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—CALCA—thyroid cancer	0.000535	0.00809	CbGpPWpGaD
Nabilone—CNR1—BDNF signaling pathway—AKT1—thyroid cancer	0.000534	0.00808	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—PRKAR1A—thyroid cancer	0.000529	0.008	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—MEN1—thyroid cancer	0.000506	0.00765	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—CDK1—thyroid cancer	0.000484	0.00732	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—PTCH1—thyroid cancer	0.000457	0.00691	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—TSHR—thyroid cancer	0.000422	0.00638	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—SST—thyroid cancer	0.000418	0.00632	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—PRKAR1A—thyroid cancer	0.000415	0.00628	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—CALCA—thyroid cancer	0.000403	0.00609	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—MEN1—thyroid cancer	0.000397	0.006	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—CDK1—thyroid cancer	0.000364	0.00551	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—PTCH1—thyroid cancer	0.000359	0.00543	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—SST—thyroid cancer	0.000328	0.00496	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—CALCA—thyroid cancer	0.000316	0.00478	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—NRG1—thyroid cancer	0.000293	0.00442	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—CDK1—thyroid cancer	0.000286	0.00432	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—TERT—thyroid cancer	0.000263	0.00397	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—HIF1A—thyroid cancer	0.000251	0.0038	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—NRG1—thyroid cancer	0.00023	0.00347	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—NRAS—thyroid cancer	0.000221	0.00335	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—BRAF—thyroid cancer	0.000208	0.00314	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—TERT—thyroid cancer	0.000206	0.00312	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—HIF1A—thyroid cancer	0.000197	0.00298	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—KRAS—thyroid cancer	0.00019	0.00288	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—NRAS—thyroid cancer	0.000174	0.00263	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—BRAF—thyroid cancer	0.000163	0.00247	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—HRAS—thyroid cancer	0.000162	0.00245	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—AKT1—thyroid cancer	0.000157	0.00238	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—CCND1—thyroid cancer	0.000152	0.0023	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—KRAS—thyroid cancer	0.000149	0.00226	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—PTEN—thyroid cancer	0.000147	0.00222	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—AKT1—thyroid cancer	0.000143	0.00216	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—NRAS—thyroid cancer	0.000131	0.00198	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—HRAS—thyroid cancer	0.000127	0.00192	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—AKT1—thyroid cancer	0.000124	0.00187	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—CCND1—thyroid cancer	0.000119	0.0018	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—PTEN—thyroid cancer	0.000115	0.00174	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—KRAS—thyroid cancer	0.000113	0.0017	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—AKT1—thyroid cancer	0.000112	0.0017	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—NRAS—thyroid cancer	0.000103	0.00155	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—TP53—thyroid cancer	0.0001	0.00151	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—HRAS—thyroid cancer	9.56e-05	0.00145	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—KRAS—thyroid cancer	8.83e-05	0.00133	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—AKT1—thyroid cancer	8.44e-05	0.00128	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—TP53—thyroid cancer	7.85e-05	0.00119	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—HRAS—thyroid cancer	7.5e-05	0.00113	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—AKT1—thyroid cancer	6.63e-05	0.001	CbGpPWpGaD
